Ocrevus (ocrelizumab) and Tysabri (natalizumab) appear equally effective at controlling relapses and MS progression, a study finds.

Researchers gathered data on patient-reported outcomes to support evidence for the continuation of natalizumab, a disease-modifying treatment, in the management of multiple sclerosis (MS) progression.

Add Yahoo as a preferred source to see more of our stories on Google. The National Institute for Health and Care Excellence (NICE) has recommended natalizumab as an option for adults with highly ...

TYSABRI is a well-established high-efficacy treatment that now provides two routes of administration enabling flexibility to meet patients' individual preferences and needs The subcutaneous option ...

Please provide your email address to receive an email when new articles are posted on . Nearly 90% of patients with relapsing-remitting MS in a multicenter study in Germany preferred subcutaneous ...

CAMBRIDGE, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) ...

April 22, 2011 — The natalizumab (Tysabri, Biogen Idec) label has been updated to further quantify the risk for progressive multifocal leukoencephalopathy (PML) in patients taking the drug. The new ...

Düsseldorf, Germany – Sept. 11, 2009 – Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) today announced six-month results of an ongoing, one-year longitudinal, observational, ...

BERLIN — When switching patients with multiple sclerosis from first-line treatments after a relapse, natalizumab (Tysabri, Biogen) appears to show a greater benefit compared with fingolimod (Gilenya, ...

Tysabri (natalizumab) helps treat forms of multiple sclerosis and Crohn’s disease. The drug comes as an infusion solution. Tysabri is not safe to receive in pregnancy and may not be safe to receive ...